1984年的帕金森病：最新情况
Parkinson's disease in 1984: an update.
作者信息
Lang A E, Blair R D
出版信息
Can Med Assoc J. 1984 Nov 1;131(9):1031-7.
Abstract
This update reviews several important topics in the field of Parkinson's disease, including etiologic studies, the types and mechanisms of drug complications and their treatment, when and how to begin treatment, the association of dementia with Parkinson's disease, and the development of the newer research tools. The recent discovery of a highly selective neurotoxin (MPTP) that causes parkinsonism in humans and other primates and the use of positron emission tomography in living patients should improve our understanding of the cause of cell death in Parkinson's disease and assist in the development of more definitive treatment for this common, disabling neurologic condition.
摘要
本次更新回顾了帕金森病领域的几个重要主题，包括病因学研究、药物并发症的类型及机制及其治疗、何时以及如何开始治疗、痴呆与帕金森病的关联以及新型研究工具的发展。最近发现一种能在人类和其他灵长类动物中导致帕金森综合征的高选择性神经毒素（MPTP），以及在活体患者中使用正电子发射断层扫描，应该会增进我们对帕金森病细胞死亡原因的理解，并有助于为这种常见的、使人致残的神经系统疾病开发更确切的治疗方法。
相似文献
1
Parkinson's disease in 1984: an update.1984年的帕金森病：最新情况
Can Med Assoc J. 1984 Nov 1;131(9):1031-7.
2
Parkinson's disease.帕金森病
Compr Ther. 1986 Mar;12(3):25-9.
3
[Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].[神经毒素1-甲基-4-苯基-1,2,3,6-四氢吡啶在特发性帕金森病病因学及治疗中的意义]
Fortschr Neurol Psychiatr. 1989 Apr;57(4):142-8. doi: 10.1055/s-2007-1000755.
4
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.联合5-HT1A和5-HT1B受体激动剂治疗左旋多巴诱导的运动障碍。
Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.
5
Development of new pharmacological approaches in Parkinson's disease.帕金森病新药理学方法的发展
Adv Neurol. 1987;45:513-8.
6
Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Mov Disord. 1989;4(3):261-5. doi: 10.1002/mds.870040307.
7
A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.一项基于医院的研究：555例接受左旋多巴治疗的帕金森病患者发生运动并发症的危险因素。
Clin Neurol Neurosurg. 2006 Dec;108(8):726-32. doi: 10.1016/j.clineuro.2006.02.002. Epub 2006 Mar 27.
8
Investigating levodopa-induced dyskinesias in the parkinsonian primate.研究帕金森病灵长类动物中左旋多巴诱发的异动症。
Ann Neurol. 2000 Apr;47(4 Suppl 1):S79-89.
9
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.帕金森病的初始治疗：左旋多巴与多巴胺受体激动剂
J Neurol. 2002 Sep;249 Suppl 2:II25-9. doi: 10.1007/s00415-002-1205-3.
10
(-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
J Neural Transm Suppl. 1986;22:107-15.
引用本文的文献
1
Essential tremor as a harbinger: What is the cognitive fallout of having essential tremor?原发性震颤作为一种先兆：原发性震颤会带来怎样的认知后果？
Int Rev Neurobiol. 2022;163:189-193. doi: 10.1016/s0074-7742(22)00057-5. Epub 2022 Jun 21.
2
Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.条件性敲除多巴胺能神经元中的 Ndufs4 可促进帕金森病样非运动症状，而不会导致多巴胺神经元丢失。
Sci Rep. 2017 Mar 22;7:44989. doi: 10.1038/srep44989.
3
Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.线粒体复合体I功能的基因下调在体内不会导致多巴胺能神经元的丧失。
Neurobiol Aging. 2015 Sep;36(9):2617-27. doi: 10.1016/j.neurobiolaging.2015.05.008. Epub 2015 May 16.
4
Differential effects of Parkinson's disease and dopamine replacement on memory encoding and retrieval.帕金森病和多巴胺替代对记忆编码和检索的影响差异。
PLoS One. 2013 Sep 26;8(9):e74044. doi: 10.1371/journal.pone.0074044. eCollection 2013.
5
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.多巴胺激动剂及其在帕金森病中诱发精神病性发作的风险：一项病例对照研究。
BMC Neurol. 2009 Jun 10;9:23. doi: 10.1186/1471-2377-9-23.
本文引用的文献
1
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.对既往未经治疗的帕金森病患者进行溴隐亭持续治疗。
J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):1020-3. doi: 10.1136/jnnp.44.11.1020.
2
Tremor, the cogwheel phenomenon and clonus in Parkinson's disease.帕金森病中的震颤、齿轮现象和阵挛。
J Neurol Neurosurg Psychiatry. 1981 Jun;44(6):534-46. doi: 10.1136/jnnp.44.6.534.
3
Lisuride in parkinsonism.利舒脲治疗帕金森病
Ann Neurol. 1981 Jan;9(1):48-52. doi: 10.1002/ana.410090109.
4
Bromocriptine: low-dose therapy in Parkinson disease.溴隐亭：帕金森病的低剂量疗法。
Neurology. 1982 Jun;32(6):577-83. doi: 10.1212/wnl.32.6.577.
5
Practical guidelines for drug holidays in parkinsonian patients.帕金森病患者药物假期实用指南。
Neurology. 1981 May;31(5):641-2. doi: 10.1212/wnl.31.5.641-b.
6
Evidence to support early levodopa therapy in Parkinson disease.
Neurology. 1981 Feb;31(2):125-31. doi: 10.1212/wnl.31.2.125.
7
Drug holiday and management of Parkinson disease.药物假期与帕金森病的管理
Neurology. 1980 Dec;30(12):1257-61. doi: 10.1212/wnl.30.12.1257.
8
[Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].[溴隐亭作为帕金森病的一线治疗。长期结果]
Rev Neurol (Paris). 1982;138(5):401-8.
9
3-O-methyldopa blocks dopa metabolism in rat corpus striatum.3 - O - 甲基多巴可阻断大鼠纹状体中的多巴代谢。
Ann Neurol. 1982 Sep;12(3):267-71. doi: 10.1002/ana.410120310.
10
New data on the genetics of Parkinson's disease.帕金森病遗传学的新数据。
Can J Neurol Sci. 1982 Feb;9(1):53-60. doi: 10.1017/s031716710004364x.
Zotero 插件